AAPS

Pauline Janssen of DFE Pharma gave a presentation on the utility of analyzing big data sets to better understand and diagnose variability in the production process.

Shawn Li, principal scientist at Merck & Co., known as MSD outside the Unites States and Canada, talked about the importance of properly characterizing HCPs in the biomanufacturing process.

At AAPS PharmSci 360, Karunakar Sukuru, RPh, PhD, the global vice-president-Rx Product Development, Pharma and Consumer Health, at Catalent Pharma Solutions, discussed lipid-based formulations and tackling bioavailability challenges for oral biologics.

Bala Addepalli, PhD, Director, R&D New Modalities Portfolio, Waters Corporation, discussed trends in new analytical tools for RNA characterization and gave highlights of his talk at AAPS PharmSci 360.

Bala Addepalli, PhD, Director, R&D New Modalities Portfolio, Waters Corporation, discussed recent advancements and current challenges in the development of large RNA therapeutics.

Redica Systems has been assisting pharmaceutical companies in determining GMP quality risks at their manufacturing sites, and with AI, it has a relatively new addition to its toolbox.

Xiao-Yan Cai, PhD, co-founder and CEO of Accurant Biotech, discussed collaborative efforts that must be undertaken between companies, and across scientific disciplines, to work together on continuing to develop medicines to save lives.

Logan Instruments discuses diffusion cell testing and what sets their company apart from other manufacturers.

Anthony Carpanzano, Director of R&D at JRS Pharma, discussed ongoing formulation challenges and trends.

Allison Labriola, Senior Technical Sales Representative, at JRS Pharma is interviewed by the Editorial Director of Pharmaceutical Technology Chris Spivey about how the food industry is affecting the pharmaceutical industry.

This video is an interview with Jon Brice, Vice President of Business Development at Asymchem at the AAPS Conference in Boston, Massachusetts.

Vibha Jawa, executive director at Bristol Myers Squibb, and Luke Schenck, principal scientist at Merck & Com, discuss cell & gene therapies and co-processed APIs respectively.